Xencor ( NASDAQ:XNCR ) First Quarter 2024 Results Key Financial Results Revenue: US$12.8m (down 33% from 1Q 2023). Net...
Comprehensive Analysis of Financial Performance and Strategic Initiatives
PASADENA, Calif., May 09, 2024--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the first quarter ended March 31, 2024 and provided a review of recent clinical and business highlights.